Acrux 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Michael Kotsanis

최고 경영자

AU$702.0k

총 보상

CEO 급여 비율	68.4%
CEO 임기	10yrs
CEO 소유권	0.5%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	10yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Michael Kotsanis 의 보수는 Acrux 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	AU$702k	AU$480k	-AU$6m
Mar 31 2024	n/a	n/a	-AU$3m
Dec 31 2023	n/a	n/a	-AU$709k
Sep 30 2023	n/a	n/a	-AU$736k
Jun 30 2023	AU$710k	AU$463k	-AU$764k
Mar 31 2023	n/a	n/a	-AU$4m
Dec 31 2022	n/a	n/a	-AU$8m
Sep 30 2022	n/a	n/a	-AU$9m
Jun 30 2022	AU$670k	AU$446k	-AU$10m
Mar 31 2022	n/a	n/a	-AU$10m
Dec 31 2021	n/a	n/a	-AU$10m
Sep 30 2021	n/a	n/a	-AU$11m
Jun 30 2021	AU$645k	AU$468k	-AU$13m
Mar 31 2021	n/a	n/a	-AU$12m
Dec 31 2020	n/a	n/a	-AU$11m
Sep 30 2020	n/a	n/a	-AU$10m
Jun 30 2020	AU$510k	AU$452k	-AU$9m
Mar 31 2020	n/a	n/a	-AU$10m
Dec 31 2019	n/a	n/a	-AU$11m
Sep 30 2019	n/a	n/a	-AU$10m
Jun 30 2019	AU$521k	AU$451k	-AU$8m
Mar 31 2019	n/a	n/a	-AU$9m
Dec 31 2018	n/a	n/a	-AU$9m
Sep 30 2018	n/a	n/a	-AU$12m
Jun 30 2018	AU$690k	AU$406k	-AU$14m

보상 대 시장: Michael 의 총 보상 ($USD 461.33K )은 German 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 483.75K ).

보상과 수익: Michael 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Michael Kotsanis (58 yo)

10yrs

테뉴어

AU$701,959

보상

Mr. Michael John Kotsanis, BSc, GradDipBus, MBus has been Chief Executive Officer and Managing Director of Acrux Limited since November 03, 2014. He served as an Independent Non-Executive Director at IDT A...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Michael Kotsanis	CEO, MD & Executive Director	10yrs	AU$701.96k	0.52% € 48.1k
Geoffrey Edward Brooke	Independent Non-Executive Director	8.4yrs	AU$84.65k	0.58% € 53.8k
Ross Dobinson	Independent Non-Executive Chairman	26.7yrs	AU$131.11k	1.81% € 167.1k
Timothy Oldham	Independent Non-Executive Director	11.1yrs	AU$84.65k	0.52% € 48.4k
Donald Brumley	Independent Non-Executive Director	3.4yrs	AU$84.01k	1.17% € 108.1k

10.0yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 이사회: FJY 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10 년).

Acrux 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Acrux Limited, Annual General Meeting, Nov 21, 2024

Insufficient new directors

Acrux Limited, Annual General Meeting, Nov 29, 2023

Independent Non-Executive Director recently bought €57k worth of stock

Acrux Limited, Annual General Meeting, Nov 23, 2022

Less than half of directors are independent

Recent updates

New major risk - Market cap size

Acrux Limited, Annual General Meeting, Nov 21, 2024

New major risk - Financial position

Full year 2024 earnings released: AU$0.02 loss per share (vs AU$0.003 loss in FY 2023)

Insufficient new directors

First half 2024 earnings released: AU$0.011 loss per share (vs AU$0.011 loss in 1H 2023)

Acrux Limited to Report First Half, 2024 Results on Feb 23, 2024

Now 40% undervalued

Acrux Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.035 loss in FY 2022)

Independent Non-Executive Director recently bought €57k worth of stock

First half 2023 earnings released: AU$0.011 loss per share (vs AU$0.019 loss in 1H 2022)

Acrux and Padagis Announce the Launch of Prilocaine and Lidocaine Cream in the United States

Acrux Limited, Annual General Meeting, Nov 23, 2022

Full year 2022 earnings released: AU$0.035 loss per share (vs AU$0.057 loss in FY 2021)

Acrux's Sixth Generic Dossier Accepted by FDA for Review

Less than half of directors are independent

Non-Executive Director recently bought €56k worth of stock

Acrux Limited Announces Fifth Generic Dossier Accepted by FDA for Review

Full year 2021 earnings released: AU$0.057 loss per share (vs AU$0.056 loss in FY 2020)

Acrux Limited Launches Testosterone Topical Solution USP, 30mg Per Actuation

CFO & Company Secretary Deborah Ambrosini has left the company

Acrux Receives Approval from the FDA for Its Generic Version of Jublia

Non Executive Director Norman Gray has left the company

Acrux Confirms Patent Challenge

Acrux Limited Announces the US Food and Drug Administration Approves its Generic Product Based on Perrigo's Testosterone Topical Solution, 30mg/1.5mL

Acrux Limited announced that it expects to receive AUD 7.815143 million in funding from Bioscience Managers Pty Ltd and other investors

Acrux Limited Signs Licensing Agreement with Dash Pharmaceuticals

Earnings released

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령